MW 436.1 Da, Purity >98%. Protein kinase C (PKC) inhibitor. Intermediate in long-chain fatty acid metabolism able to disrupt cell membranes.
Also available in simple stock solutions (ab146730) - add 1 ml of water to get an exact, ready-to-use concentration.
BAR, Bile acid receptor, Cytosolic NADP-isocitrate dehydrogenase, DNA replication inhibitor, Epididymis luminal protein 216, Epididymis secretory protein Li 26, Farnesoid X-activated receptor, Farnesol receptor HRR-1, GEMI_HUMAN, GMNN, Geminin, Geminin DNA replication inhibitor, HEL-216, HEL-S-26, HRR 1, HS90A_HUMAN, HSP 84, HSP 86, HSP 90, HSP 90 b, HSP90A, HSP90AA1, HSP90AB1, HSPC1, HSPC2, HSPCAL1, HSPCAL4, Heat shock 86 kDa, Heat shock protein 90kDa alpha cytosolic class A member 1, Heat shock protein 90kDa alpha cytosolic class B member 1, Heat shock protein HSP 90-alpha, Heat shock protein HSP 90-beta, ICDH, IDCD, IDH, IDH1, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, OTTHUMP00000039393, Oxalosuccinate decarboxylase, PICD, RIP 14, RP3 369A17.3, RXR-interacting protein 14, Renal carcinoma antigen NY-REN-38, Retinoid X receptor-interacting protein 14
MW 436.1 Da, Purity >98%. Protein kinase C (PKC) inhibitor. Intermediate in long-chain fatty acid metabolism able to disrupt cell membranes.
Also available in simple stock solutions (ab146730) - add 1 ml of water to get an exact, ready-to-use concentration.
Soluble in water to 10 mM.
Protein kinase C (PKC) inhibitor. Intermediate in long-chain fatty acid metabolism able to disrupt cell membranes.
Also available in simple stock solutions (ab146730) - add 1 ml of water to get an exact, ready-to-use concentration.
Hsp90 Geminin and IDH1 represent different yet significant proteins with distinct mechanical functions. Heat shock protein 90 (Hsp90) acts as a molecular chaperone stabilizing and folding other proteins with a molecular weight of around 90 kDa. It plays an important role in maintaining cellular protein homeostasis and is expressed across various cell types. Additionally Hsp90 interacts with multiple client proteins including protein kinase C (PKC) serving as a chaperone to ensure their functional conformation. Geminin acts as a DNA replication inhibitor by preventing the re-replication of DNA during the cell cycle. It is ubiquitously expressed in proliferating cells and has implications in cell cycle regulation. IDH1 (Isocitrate dehydrogenase 1) having a mass of approximately 47 kDa catalyzes the conversion of isocitrate to alpha-ketoglutarate in the cytoplasm and is most prominently expressed in the liver among other tissues.
Hsp90 chaperones stabilize numerous signaling proteins contributing to essential cellular processes such as cell growth and apoptosis. It forms a complex with co-chaperones to facilitate the folding and activation of client proteins some of which are critical oncogenes. Geminin inhibits DNA replication by binding to Cdt1 preventing it from initiating re-replication within a single cell cycle. This regulation ensures genomic integrity during cell division. IDH1 participates in cellular metabolism by contributing to the citric acid cycle and plays a role in protecting cells from oxidative damage through the production of NADPH.
Hsp90 is integral to the signal transduction and stress response pathways interacting with proteins like protein kinase C (PKC) and steroid hormone receptors. These pathways are critical for cellular response to external stimuli and stress as well as for regulating cell cycle progression. Geminin is part of the DNA replication and cell cycle pathways; it regulates the transition between G1 and S phases in conjunction with cyclins and CDKs. IDH1 contributes to metabolic pathways including the citric acid cycle and lipid biosynthesis by regulating energy production and reducing equivalents.
Aberrant Hsp90 activity links to various cancers including breast cancer due to its role in stabilizing oncogenic proteins such as mutant PKC. Targeting Hsp90 can disrupt these protein interactions and contribute to potential cancer therapies. Geminin's dysregulation can lead to unregulated DNA replication and in turn tumorigenesis as seen in certain aneuploid cancers. IDH1 mutations are associated with metabolic disorders like glioma altering the cell’s metabolic state and contributing to oncogenesis. In gliomas IDH1 mutation produces the onco-metabolite 2-hydroxyglutarate which can interfere with cellular differentiation and contribute to the disease progression.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure of ab141122, (±)-Palmitoylcarnitine chloride, Protein kinase C (PKC) inhibitor
ab59720 staining ZO1 in Caco-2 cells treated with (±)-palmitoylcarnitine chloride (ab141122), by ICC/IF. Membranar ZO1 expression loss correlates with increased concentration of (±)-palmitoylcarnitine chloride, as described in literature.
The cells were incubated at 37°C for 1 hour in media containing different concentrations of ab141122 ((±)-palmitoylcarnitine chloride) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab59720 (0.5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com